Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer

HER2-positive breast cancer patients carrying the germline TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) are resistant to anti-HER2 therapy. Multi-predictor in silico analysis reveals that this variant is deleterious. We explore the potential mechanism of this TSC2 variant and investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ziyan, Feng, Jianguo, Jing, Ji, Huang, Yuan, Ye, Wei-Wu, Lei, Lei, Wang, Xiao-Jia, Cao, Wen-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170158/
https://www.ncbi.nlm.nih.gov/pubmed/37160904
http://dx.doi.org/10.1038/s41523-023-00542-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170158/
https://www.ncbi.nlm.nih.gov/pubmed/37160904
http://dx.doi.org/10.1038/s41523-023-00542-1

Ejemplares similares